“We are excited about Louisa joining our Board. With a strong track-record of business leadership and growing consumer and pharmaceutical brands in Canada, Louisa will be a tremendous addition to our Board. We believe her deep experience and expertise broadly in healthcare and in consumer products will be invaluable as we advance our portfolio of products. We look forward to her contributions,” said Dr. Joseph Gabriele, CEO of Delivra. We also wish to thank David for his contributions as a director, since the Company’s public listing. He has been an asset to our Board and our business.”
Louisa has led across a number of senior roles, with a strong track record over more than 20-years. Most recently, President & Managing Director of the Johnson & Johnson Consumer Group of Companies in Canada, where she led the $1 billion Canadian consumer business. Louisa has also served as a member of Johnson & Johnson’s North American Leadership Team. Outside of Johnson & Johnson, she has served as a board member on multiple industry associations, including as a member of the Finance Committee of Canadian Health Products Canada. Louisa has an active role in the community, currently serving as an Academic Mentor for the Rotman School of Management, a member of 30% Club Canada Advisory Committee and a member of Women in Philanthropy for Providence Advisory team. She and her family dedicate time and energy to Free the Children locally and globally. Louisa received her Pharmacy degree from the University of Toronto and MBA from Ivey School of Business, University of Western Ontario. She completed the Institute of Corporate Directors (ICD) Education Program at the Rotman School of Management, University of Toronto.
Grant of Stock Options
The Company also announces that, subject to regulatory approval, it has granted stock options in the amount of 137,500 to certain members of the Board of Directors under the Company’s Stock Option Plan. Each stock option is exercisable for a five-year period to acquire one common share at a price of $0.455 per share. The options vest 50% on the first anniversary date and 50% on the second anniversary date.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. LivReliefTM products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivReliefTM pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its Canada and US consumer products business, Delivra also has a mandate to license its over-the-counter products in other countries and its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies for the repurposing of pharmaceutical molecules in the treatment of a broad range of conditions. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.
The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.
For more information, please contact:
416-238-1414 x 233